The development of novel agents such as monoclonal antibodies (anti-CD20), anti-CD19 bispecific T-cell engager (blinatumomab), and anti-CD22 antibody-drug conjugate (inotuzumab ozogamicin) has provided excellent results in both upfront and r/r ALL and continues to change the treatment paradigm for ALL (15–18). Here, CD19 is linked to acute lymphoblastic leukemia.